"From routine appointments to emergency services, it’s important to get the care you need—when you need it. But we understand you may be delaying your health needs over concerns about safety. At Mount Sinai, our doctors, nurses, and staff members are working continuously to ensure your safety so that you don't have to put your health on hold."

During the past decade, Mount Sinai Brooklyn conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Mount Sinai Brooklyn" are "Multiple Myeloma" (1 trials) and "SARS-CoV2 Infection" (1 trials). Many other conditions were trialed in "Mount Sinai Brooklyn" in a lesser frequency.

Most popular intervention types in "Mount Sinai Brooklyn" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bortezomib" (1 trials), "CC-220" (1 trials), "Carfilzomib" (1 trials), "Daratumumab" (1 trials) and "Dexamethasone" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mount Sinai Brooklyn" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Mount Sinai Brooklyn". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Mount Sinai Brooklyn, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Mount Sinai Brooklyn, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".